{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:02:59Z","timestamp":1790128979623,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["205217"],"award-info":[{"award-number":["205217"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2017080"],"award-info":[{"award-number":["2017080"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Melanoma patients with metastatic growth in the meninges have poor prognosis and few treatment options. Although treatment with BRAF inhibitors or immune checkpoint inhibitors has provided promising results, most patients with advanced melanoma are resistant to these treatments and develop severe side effects. Novel treatment strategies are needed for patients with meningeal melanoma metastases, and the potential of antiangiogenic therapy was investigated in this preclinical study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Two GFP-transfected melanoma models (A-07 and D-12) differing substantially in VEGF-A expression were included in the study, and the anti-VEGF-A antibody bevacizumab was used as therapeutic agent. Meningeal metastases were initiated in BALB\/c <jats:italic>nu<\/jats:italic>\/<jats:italic>nu<\/jats:italic> mice by intracranial inoculation of melanoma cells, and bevacizumab treatment was given twice a week in i.p. doses of 10\u00a0mg\/kg until the mice became moribund. Therapeutic effects were evaluated by determining tumor host survival time, assessing tumor growth and angiogenic activity by quantitative analyses of histological preparations, and measuring the expression of angiogenesis-related genes by quantitative PCR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Meningeal A-07 melanomas showed higher expression of VEGF-A than meningeal D-12 melanomas, whereas the expression of ANGPT2 and IL8, two important angiogenesis drivers in melanoma, was much higher in D-12 than in A-07 tumors. Bevacizumab treatment inhibited tumor angiogenesis and prolonged host survival in mice with A-07 tumors but not in mice with D-12 tumors. Meningeal A-07 tumors in bevacizumab-treated mice compensated for the reduced VEGF-A activity by up-regulating a large number of angiogenesis-related genes, including ANGPT2 and its receptors TIE1 and TIE2. Melanoma cells migrated from meningeal tumors into the cerebrum, where they initiated metastatic growth by vessel co-option. In the A-07 model, the density of cerebral micrometastases was higher in bevacizumab-treated than in untreated mice, either because bevacizumab treatment increased mouse survival or induced increased tumor gene expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The development of antiangiogenic strategies for the treatment of meningeal melanoma metastases is a challenging task because the outcome of treatment will depend on the angiogenic signature of the tumor tissue, treatment-induced alterations of the angiogenic signature, and the treatment sensitivity of metastatic lesions in other intracranial sites.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-020-02212-3","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T11:02:57Z","timestamp":1578481377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bevacizumab treatment of meningeal melanoma metastases"],"prefix":"10.1186","volume":"18","author":[{"given":"Trude G.","family":"Simonsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon-Vidar","family":"Gaustad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar K.","family":"Rofstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"issue":"Suppl 11","key":"2212_CR1","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/cncr.30594","volume":"123","author":"D Westphal","year":"2017","unstructured":"Westphal D, Glitza Oliva IC, Niessner H. Molecular insights into melanoma brain metastases. Cancer. 2017;123(Suppl 11):2163\u201375.","journal-title":"Cancer"},{"key":"2212_CR2","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117:1687\u201396.","journal-title":"Cancer"},{"key":"2212_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO;2-E","volume":"42","author":"MH Amer","year":"1978","unstructured":"Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42:660\u20138.","journal-title":"Cancer"},{"key":"2212_CR4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1586\/ern.12.111","volume":"12","author":"E Fonkem","year":"2012","unstructured":"Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, et al. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother. 2012;12:1207\u201315.","journal-title":"Expert Rev Neurother"},{"key":"2212_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1215\/15228517-2007-058","volume":"10","author":"JJ Raizer","year":"2008","unstructured":"Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10:199\u2013207.","journal-title":"Neuro Oncol."},{"key":"2212_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/pcmr.12538","volume":"29","author":"JV Cohen","year":"2016","unstructured":"Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, et al. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2016;29:627\u201342.","journal-title":"Pigment Cell Melanoma Res."},{"key":"2212_CR7","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/neuonc\/now197","volume":"19","author":"MC Chamberlain","year":"2017","unstructured":"Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQM. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol. 2017;19:i1\u201324.","journal-title":"Neuro Oncol."},{"key":"2212_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/CCO.0b013e32833de986","volume":"22","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol. 2010;22:627\u201335.","journal-title":"Curr Opin Oncol"},{"key":"2212_CR9","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.1253735","volume":"346","author":"JA Lo","year":"2014","unstructured":"Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science. 2014;346:945\u20139.","journal-title":"Science"},{"key":"2212_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11864-016-0421-5","volume":"17","author":"K Margolin","year":"2016","unstructured":"Margolin K. The promise of molecularly targeted and immunotherapy for advanced melanoma. Curr Treat Options Oncol. 2016;17:48.","journal-title":"Curr Treat Options Oncol"},{"key":"2212_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11940-017-0449-2","volume":"19","author":"AS Berghoff","year":"2017","unstructured":"Berghoff AS, Preusser M. Targeted therapies for melanoma brain metastases. Curr Treat Options Neurol. 2017;19:13.","journal-title":"Curr Treat Options Neurol."},{"key":"2212_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/0002-9610(78)90171-X","volume":"135","author":"JK Patel","year":"1978","unstructured":"Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807\u201310.","journal-title":"Am J Surg."},{"key":"2212_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrc3053","volume":"11","author":"PS Steeg","year":"2011","unstructured":"Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011;11:352\u201363.","journal-title":"Nat Rev Cancer"},{"key":"2212_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/jclinpath-2015-203482","volume":"69","author":"G Jour","year":"2016","unstructured":"Jour G, Ivan D, Aung PP. Angiogenesis in melanoma: an update with a focus on current targeted therapies. J Clin Pathol. 2016;69:472\u201383.","journal-title":"J Clin Pathol"},{"key":"2212_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391\u2013400.","journal-title":"Nat Rev Drug Discov."},{"key":"2212_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(14)70110-X","volume":"15","author":"PG Corrie","year":"2014","unstructured":"Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, et al. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol. 2014;15:620\u201330.","journal-title":"Lancet Oncol."},{"key":"2212_CR17","first-page":"341","volume":"62","author":"B Kusters","year":"2002","unstructured":"Kusters B, Leenders WP, Wesseling P, Smits D, Verrijp K, Ruiter DJ, et al. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 2002;62:341\u20135.","journal-title":"Cancer Res"},{"key":"2212_CR18","first-page":"5408","volume":"63","author":"B Kusters","year":"2003","unstructured":"Kusters B, de Waal RM, Wesseling P, Verrijp K, Maass C, Heerschap A, et al. Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. Cancer Res. 2003;63:5408\u201313.","journal-title":"Cancer Res"},{"key":"2212_CR19","first-page":"4185","volume":"58","author":"T Oku","year":"1998","unstructured":"Oku T, Tjuvajev JG, Miyagawa T, Sasajima T, Joshi A, Joshi R, et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res. 1998;58:4185\u201392.","journal-title":"Cancer Res"},{"key":"2212_CR20","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1158\/0008-5472.CAN-05-2674","volume":"66","author":"TX Xie","year":"2006","unstructured":"Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006;66:3188\u201396.","journal-title":"Cancer Res"},{"key":"2212_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/1535-7163.MCT-15-0582","volume":"15","author":"A Ilhan-Mutlu","year":"2016","unstructured":"Ilhan-Mutlu A, Osswald M, Liao YX, Gommel M, Reck M, Miles D, et al. Bevacizumab prevents brain metastases formation in lung adenocarcinoma. Mol Cancer Ther. 2016;15:702\u201310.","journal-title":"Mol Cancer Ther"},{"issue":"18 Pt 1","key":"2212_CR22","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-04-0823","volume":"10","author":"WP Leenders","year":"2004","unstructured":"Leenders WP, Kusters B, Verrijp K, Maass C, Wesseling P, Heerschap A, et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res. 2004;10(18 Pt 1):6222\u201330.","journal-title":"Clin Cancer Res"},{"key":"2212_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nm.2072","volume":"16","author":"Y Kienast","year":"2010","unstructured":"Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010;16:116\u201322.","journal-title":"Nat Med"},{"key":"2212_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1046\/j.1365-2362.2003.01056.x","volume":"33","author":"JC Reijneveld","year":"2003","unstructured":"Reijneveld JC, Taphoorn MJB, Kerckhaert OAJ, Drixler TA, Boogerd W, Voest EE. Angiostatin prolongs the survival of mice with leptomeningeal metastases. Eur J Clin Investig. 2003;33:76\u201381.","journal-title":"Eur J Clin Investig"},{"key":"2212_CR25","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/neuonc\/not112","volume":"15","author":"AS Berghoff","year":"2013","unstructured":"Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, et al. Invasion patterns in brain metastases of solid cancers. Neuro Oncol. 2013;15:1664\u201372.","journal-title":"Neuro Oncol."},{"key":"2212_CR26","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/DAD.0b013e31827e8315AD","volume":"35","author":"T Hung","year":"2013","unstructured":"Hung T, Morin J, Munday WR, Mackenzie IR, Lugassy C, Barnhill RL. Angiotropism in primary cutaneous melanoma with brain metastasis: a study of 20 cases. Am J Dermatopathol. 2013;35:650\u20134.","journal-title":"Am J Dermatopathol"},{"key":"2212_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13046-015-0264-0","volume":"34","author":"TG Simonsen","year":"2015","unstructured":"Simonsen TG, Gaustad JV, Rofstad EK. Intertumor heterogeneity in vascularity and invasiveness of artificial melanoma brain metastases. J Exp Clin Cancer Res. 2015;34:150.","journal-title":"J Exp Clin Cancer Res."},{"key":"2212_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/sj.bjc.6601953","volume":"91","author":"U Herrlinger","year":"2004","unstructured":"Herrlinger U, Wiendl H, Renninger M, Forschler H, Dichgans J, Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer. 2004;91:219\u201324.","journal-title":"Br J Cancer."},{"key":"2212_CR29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/bjc.1994.403","volume":"70","author":"EK Rofstad","year":"1994","unstructured":"Rofstad EK. Orthotopic human melanoma xenograft model systems for studies of tumor angiogenesis, pathophysiology, treatment sensitivity and metastatic pattern. Br J Cancer. 1994;70:804\u201312.","journal-title":"Br J Cancer"},{"key":"2212_CR30","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1080\/095530099139250","volume":"75","author":"EK Rofstad","year":"1999","unstructured":"Rofstad EK, M\u00e5seide K. Radiobiological and immunohistochemical assessment of hypoxia in human melanoma xenografts: acute and chronic hypoxia in individual tumours. Int J Radiat Biol. 1999;75:1377\u201393.","journal-title":"Int J Radiat Biol"},{"key":"2212_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1006\/mvre.2001.2303","volume":"61","author":"BA Graff","year":"2001","unstructured":"Graff BA, Bj\u00f8rn\u00e6s I, Rofstad EK. Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression. Microvasc Res. 2001;61:187\u201398.","journal-title":"Microvasc Res"},{"key":"2212_CR32","doi-asserted-by":"publisher","first-page":"e40006","DOI":"10.1371\/journal.pone.0040006","volume":"7","author":"TG Simonsen","year":"2012","unstructured":"Simonsen TG, Gaustad JV, Leinaas MN, Rofstad EK. High interstitial fluid pressure is associated with tumor-line specific vascular abnormalities in human melanoma xenografts. PLoS ONE. 2012;7:e40006.","journal-title":"PLoS ONE"},{"key":"2212_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2144\/000112776","volume":"44","author":"HD VanGuilder","year":"2008","unstructured":"VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques. 2008;44:619\u201326.","journal-title":"Biotechniques"},{"key":"2212_CR34","first-page":"4932","volume":"60","author":"EK Rofstad","year":"2000","unstructured":"Rofstad EK, Hals\u00f8r EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 2000;60:4932\u20138.","journal-title":"Cancer Res"},{"key":"2212_CR35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/1471-2407-12-388","volume":"12","author":"JV Gaustad","year":"2012","unstructured":"Gaustad JV, Simonsen TG, Leinaas MN, Rofstad EK. Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts. BMC Cancer. 2012;12:388.","journal-title":"BMC Cancer."},{"key":"2212_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12967-017-1307-4","volume":"15","author":"R Huang","year":"2017","unstructured":"Huang R, Andersen LMK, Rofstad EK. Metastatic pathway and the microvascular and physicochemical microenvironments of human melanoma xenografts. J Transl Med. 2017;15:203.","journal-title":"J Transl Med."},{"key":"2212_CR37","first-page":"95","volume":"136","author":"G Schackert","year":"1990","unstructured":"Schackert G, Price JE, Zhang RD, Bucana CD, Itoh K, Fidler IJ. Regional growth of different human melanomas as metastases in the brain of nude mice. Am J Pathol. 1990;136:95\u2013102.","journal-title":"Am J Pathol"},{"key":"2212_CR38","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M Paez-Ribes","year":"2009","unstructured":"Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220\u201331.","journal-title":"Cancer Cell"},{"key":"2212_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JML Ebos","year":"2009","unstructured":"Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232\u20139.","journal-title":"Cancer Cell"},{"key":"2212_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrc745","volume":"2","author":"M Egeblad","year":"2002","unstructured":"Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161\u201374.","journal-title":"Nat Rev Cancer."},{"key":"2212_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13046-018-0763-x","volume":"37","author":"R Huang","year":"2018","unstructured":"Huang R, Rofstad EK. Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma. J Exp Clin Cancer Res. 2018;37:92.","journal-title":"J Exp Clin Cancer Res."},{"key":"2212_CR42","doi-asserted-by":"publisher","first-page":"6699","DOI":"10.1158\/0008-5472.CAN-06-0983","volume":"66","author":"EK Rofstad","year":"2006","unstructured":"Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006;66:6699\u2013707.","journal-title":"Cancer Res"},{"key":"2212_CR43","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1097\/NEN.0b013e31818f9ca8","volume":"67","author":"T Owens","year":"2008","unstructured":"Owens T, Bechmann I, Engelhardt B. Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol. 2008;67:1113\u201321.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2212_CR44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/PPO.0000000000000126","volume":"21","author":"IJ Fidler","year":"2015","unstructured":"Fidler IJ. The biology of brain metastasis: challenges for therapy. Cancer J. 2015;21:284\u201393.","journal-title":"Cancer J"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02212-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-020-02212-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02212-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:47:54Z","timestamp":1609980474000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02212-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2212"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02212-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"30 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal experiments were approved by the Institutional Committee on Research Animal Care, Department of Comparative Medicine, Oslo University Hospital, Norway and the Norwegian Food Safety Authority, Brummundal, Norway (approved protocol: FOTS ID 10422). The use of human tissue for establishing the melanoma models was approved by our institution (Committee for Medical and Health Research Ethics).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}